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UNDERSTANDING THE ROLE OF THE BED NUCLEUS OF THE STRIA 
TERMINALIS IN ALCOHOL USE DISORDERS 
RACHEL LEAVITT 
 
ABSTRACT 
 
Alcohol Use Disorders (AUDs) have devastating economic, mortality, and public 
health implications on society. Repeated cycles of alcohol intoxication and abstinence are 
known to induce neuroplastic alterations in specific brain regions, alterations which in 
turn trigger and sustain excessive alcohol drinking. The Bed Nucleus of the Stria 
Terminalis (BNST) has been proposed as a critical brain site for neuroadaptations 
induced by chronic alcohol. The Pituitary Adenylate-Cyclase Activating Polypeptide 
(PACAP) system highly expressed in the BNST, has been proposed to be a master 
regulator of the stress response. These experiments aimed to investigate the role of the 
PACAP system of the BNST in alcohol drinking. Using a two-bottle choice chronic 
intermittent ethanol paradigm, we demonstrated that excessive intermittent alcohol 
consumption causes a marked increase in PACAP immunoreactivity in the BNST of 
mice. In addition, we observed a significant higher PACAP expression in the BNST of 
female, compared to male mice.  These data lay the foundation for more extensive studies 
which may lead to the identification of a neuropeptide system with a critical role in heavy 
alcohol drinking.  A deeper understanding of the specific neuroadaptations produced by 
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chronic alcohol will be essential for the discovery of novel therapeutic agents to alleviate 
alcoholism.    
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INTRODUCTION 
Alcohol Use Disorders 
Alcohol Use Disorders, or AUDs, have devastating economic and public health 
implications on society. The World Health Organization’s 2014 Global Status report on 
Alcohol and Health reports that 3.3 million deaths in 2012 were attributable to alcohol 
consumption. In addition to societal costs due to alcohol consumption, individuals also 
experience personal costs to themselves and their families. These costs are measured by 
the loss of life quality, pain and anguish, both emotional and physical (World Health 
Organization. Management of Substance Abuse Team. 2011). It is also important to note 
that AUDs occur more frequently in adult men (12.4%) than adult women (4.5%) 
however, females are more likely to reach higher blood alcohol levels (BALs) than their 
male counterparts consuming the same drink, because of both lower body weights and 
body water content, and higher body fat composition (American Psychiatric Association, 
2013a). 
AUDs are diagnosed based on the DSM-V, as meeting at least two of the eleven 
criteria listed below, within the last twelve months:  
1) Alcohol is often taken in larger amounts or over a longer period than was intended; 2) 
There is a persistent desire or unsuccessful efforts to cut down or control alcohol use; 3) 
A great deal of time is spent in activities necessary to obtain alcohol, use alcohol, or 
recover from its effects; 4) Craving, or a strong desire or urge to use alcohol; 5) 
Recurrent alcohol use resulting in a failure to fulfill major role obligations at work, 
school, or home; 6) Continued alcohol use despite having persistent or recurrent social or 
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interpersonal problems caused or exacerbated by the effects of alcohol; 7) Important 
social, occupational, or recreational activities are given up or reduced because of alcohol 
use; 8) Recurrent alcohol use in situations in which it is physically hazardous; 9) Alcohol 
use is continued despite knowledge of having a persistent or recurrent physical or 
psychological problem that is likely to have been caused or exacerbated by alcohol; 10) 
Tolerance, as defined by either of the following: A need for markedly increased amounts 
of alcohol to achieve intoxication or desired effect, or a markedly diminished effect with 
continued use of the same amount of alcohol; and 11) Withdrawal, as manifested by 
either of the following: the characteristic withdrawal syndrome for alcohol or alcohol (or 
a closely related substance, such as a benzodiazepine) is taken to relieve or avoid 
withdrawal symptoms (American Psychiatric Association 2013b). 
AUDs are highly comorbid with other psychiatric disorders such as 
schizophrenia, bipolar disorder, antisocial personality disorder, as well as depressive and 
anxiety disorders (American Psychiatric Association 2013a). Conversely, these 
psychiatric disorders may put individuals at risk for alcohol dependence when self-
medication with alcohol is used to alleviate pre-existing symptoms (Gilpin and Koob 
2008). Despite the high prevalence of AUDs, there remains a lack of diverse and 
effective treatments for alcohol dependence, or alcoholism. 
Currently, there are only three FDA-approved drugs to treat AUDs: naltrexone, 
acamprosate, and disulfiram. Naltrexone is an opioid receptor blocker, which inhibits 
cravings and blocks the rewarding effects of alcohol (Liu et al. 2014). Acamprosate, the 
calcium salt of N-acetyl-homotaurin, is a synthetic analogue of the amino acid gamma-
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aminobutyric acid (GABA) with a complex and still debated mechanism of action (Heilig 
2014). Disulfiram is an aldehyde dehydrogenase inhibitor, which causes aversive 
reactions if alcohol is consumed due to acetaldehyde accumulation (Hald and Jacobsen 
1948; Johansson 1992). However, not all patients respond to these drugs, and issues of 
side effects also reduce compliance.  
 
Neurobiology of Alcohol Addiction 
Addiction is a chronic, relapsing brain disease that is characterized by the 
compulsion to seek and take drug/alcohol, an inability to control the amount used, and a 
negative emotional state that arises when the substance cannot be accessed (Gilpin and 
Koob 2008). Alcohol addiction has been hypothesized to evolve from impulsive use to 
compulsive need through repeated cycles of intoxication and withdrawal, which result in 
profound neuroadaptations in specific areas of the brain (Cui et al. 2013; Koob 2013). 
There are three widely recognized stages of alcohol use that overlap and 
ultimately contribute to the progressive transition from alcohol use to alcohol 
dependence. They are: 1) binge and intoxication, 2) withdrawal and negative affect, and 
3) pre-occupation and anticipation, better known as craving (Volkow et al. 2016). 
Neuroadaptations within the addiction circuitry and the progressive transition from 
alcohol use to dependence hinge on the repeated cycling of these three stages. 
Acute alcohol consumption stimulates the release of dopamine, which activates 
the brain reward circuitry. All addictive substances elicit this initial response (Di Chiara 
2002; Koob 1992; Wise 2008). Research on the neurobiology of addiction has focused on 
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the positive reinforcing effects and the activation of the mesocorticolimbic dopamine 
system following acute drug administration. The mesocorticolimbic pathway is a 
dopaminergic pathway that connects the ventral tegmental area (VTA) to the nucleus 
accumbens (NAcc), as well as other limbic and cortical regions (Gilpin and Koob 2008). 
This circuit helps shape incentive salience, better known as the “wanting” or “desire” for 
alcohol (Berridge 2007; Robinson and Berridge 1993). In animal models of alcohol 
consumption, oral ethanol self-administration is reduced by the administration of 
dopamine and N-methyl-D-aspartate (NMDA) receptor antagonists into the NAcc 
(Rassnick et al. 1992). Alcohol ingestion as well as the anticipation of alcohol has been 
shown to cause an increase in extracellular dopamine levels in the NAcc (Weiss et al. 
1993). However, it was also shown that 6-hydroxydopamine (6-OHDA)-induced lesions 
of the mesolimbic dopamine system is not sufficient to block alcohol self-administration 
(Rassnick et al. 1993). On the contrary, subjects undergoing alcohol withdrawal have 
been shown to display lower levels of dopamine, as compared to controls, suggesting a 
hypodopaminergic state (Karkhanis et al. 2015; Volkow et al. 2007).  
In later stages, a shift from occasional alcohol use to alcohol dependence occurs, 
which parallels a switch from positive reinforcement to negative reinforcement as the 
motivating factor behind alcohol use; this switch is thought to be produced by 
neuroplastic changes elicited by chronic alcohol exposure (Gilpin and Koob 2008).  
Repeated exposure to the stress response leads to development of negative emotions and 
increased reactivity to stress (Davis et al. 2010; Jennings et al. 2013). In the withdrawal 
and negative affect stage, rewards are no longer the potent positive reinforcers they were 
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at the origin of drug use. The brain reward system becomes desensitized to drug and non-
drug related rewards (Hagele et al. 2015; Hyatt et al. 2012; Konova et al. 2012) (Volkow 
et al. 2014; Volkow et al. 2006; Zhang 2013). This stage involves neurocircuitries of the 
extended amygdala and the activation of brain’s stress neurotransmitter systems, such as 
the corticotropin-releasing factor (CRF) and the dynorphin (Volkow et al. 2016).   
The last stage of addiction is the preoccupation and anticipation. This stage is 
characterized by profound deficits in prefrontal cortex function, which result in the 
serious impairment of judgment and self-regulation (Goldstein and Volkow 2011). In 
addition, the prefrontal cortex becomes hyperreactive to cues previously associated with 
alcohol. 
 
Bed Nucleus of the Stria Terminalis (BNST) and its role in the actions of alcohol 
The Bed Nucleus of the Stria Terminalis (BNST) is a brain structure located in the 
basal forebrain (Avery et al. 2016; Lebow and Chen 2016). It contains 12-18 subnuclei, 
each with diverse receptors, transporters, neurotransmitters, and proteins (Lebow and 
Chen 2016). BNST neurons have been shown to express different neuropeptides, such as 
CRF, enkephalin (ENK), neuropeptide Y (NPY), neurotensin, and somatostatin (SST). 
These neuropeptides show different immunoreactivity in each of the BNST subregions, 
confirming the diverse makeup and function of each subregion of the BNST (Walter et al. 
1991). The BNST contains mostly GABAergic neurons (Kash 2012; Kozicz et al. 1997) 
and some glutamatergic neurons principally located in the ventral BNST (Daniel and 
Rainnie 2016; Jennings et al. 2013). The BNST acts as a key relay for many neuronal 
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pathways. It receives glutamatergic projections from thalamic, cortical, and amygdalar 
regions and GABAergic projections from the amygdalar region. The brainstem and 
hypothalamus send modulatory inputs to it, and then projects back to all these areas in 
varying degrees (Kash 2012).  
It is also important to note that steroid hormones receptors such as androgen, 
estrogen (both alpha and beta subtypes) and progesterone are located in the BNST 
(Frazier et al. 2006; He et al. 2014; Laflamme et al. 1998), possibly influencing states of 
sustained fear and anxiety both sexes and attachment of proper valence to situations 
(Lebow et al. 2012). Steroid hormone manipulation affects anxiety-related behaviors; 
more specifically, progesterone reduces CRF-enhanced startle and stimulates BNST 
neurons via oxytocin (Wakerley et al. 1998). Male rats had reduced light enhanced startle 
because of testosterone. Because of these effects of testosterone, intact males hold the 
lowest light-potentiated startle; pregnant females possess the highest (Toufexis 2007). 
Anatomical sex differences also exist, such as human females boasting a 76% greater 
structural connectivity in the BNST (Avery et al. 2014). Male rodents possess a larger 
Arginine Vasopressin Pathway (AVP) from the BNST to the lateral septum (De Vries 
and al-Shamma 1990; Miller et al. 1989) and hypogonadism reduces BNST AVP 
immunoreactivity (Rosie et al. 1993; Viau et al. 2001). Sex differences in anatomy, 
anxiety-related receptors, and behavior of the BNST may contribute to the immense 
difference in human psychiatric diseases prevalence rates between men and women. 
The BNST has been identified as a key component of the extended amygdala, 
which also includes the central nucleus of the amygdala (CeA) (Avery et al. 2016). These 
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brain regions have comparable neural inputs and outputs, neurochemical components, 
and cell types (Alheid et al. 1998). Though the BNST and CeA are similar, the BNST 
mediates sustained anxiety states and contextual fears, as opposed to the CeA, which 
plays a role in acute fear responses (Kash 2012; Waraczynski 2016). The CeA is 
responsible for responding to perceived immediate danger, or conditioned fear, which is 
signaled by discrete sensory cues, such as tones or light cues; BNST lesions do not effect 
this response in subjects, suggesting that conditioned fear responses are specific to the 
CeA (Gewirtz et al. 2000; LeDoux et al. 1988; Sullivan et al. 2004; Walker and Davis 
1997).  
Anterolateral BNST activation increases plasma levels of CRF (Dunn 1987); 
lesions on this area have been shown to lead to a decrease in CRF plasma levels (Herman 
et al. 1994) and subsequently to decreases in ACTH and corticosterone levels (Gray et al. 
1993). Posterior and medial regions demonstrate the ability to cause anxiolytic effects 
(anxiolytic) (Dunn 1987; Herman et al. 1994) which validates the theory that different 
BNST subregions mediate different aspects of the stress responses.  
Kim et al demonstrated that if GABAergic signals from the oval BNST to the 
anterodorsal BNST (adBNST) are active and glutamatergic signals from the basolateral 
amygdala (BLA) to the adBNST are inactive, glutamatergic projections from the 
adBNST to the parabrachial nucleus (PBN), ventral tegmental area (VTA), and the lateral 
hypothalamus (LH) are inhibited. This inhibition causes an elevated respiration, 
avoidance of stress-associated places, and a decrease in open field exploration. On the 
other hand, when the BLA glutamatergic projections activate, they activate the adBNST, 
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which projects GABAergic neurons to the PVN. The results are a decrease in respiration 
and an increase in open field exploration and place preferences (Kim et al. 2013).  
This was also exemplified in a study carried out by Jennings et al by mapping the 
stimulated projections from the BNST to the non-dopaminergic neurons of the VTA, 
using channelrhodopsin-2 (CR-2). By photostimulating glutamatergic projections in the 
BNST, anxiogenic and aversive effects can be initiated. On the other hand, 
photostimulation of GABAergic projections produced anxiolytic and rewarding effects. 
Direct inhibition of GABA neurons in the VTA reconfirmed this point (Jennings et al. 
2013). 
Just as the BNST modulates chronic stress, chronic stress shapes BNST function 
through structural and functional changes. Expression of CRF in the BNST increases 
after chronic social and "mild" stress, in addition to chronic corticosterone treatment 
(Makino et al. 1994; Schulkin et al. 1994; Watts and Sanchez-Watts 1995). These stress-
inducing paradigms have been implicated in BNST volume and dendritic length increases 
(Pego et al. 2008), as well as account for a greater number of BNST dendritic branches 
(Vyas et al. 2003; Vyas et al. 2002). These stress response reactionary neuroadaptations 
could be responsible for the development of anxiety disorders, such as post-traumatic 
stress disorder (PTSD), general anxiety disorder (GAD), or antisocial behavior and 
aggression (Lebow and Chen 2016), as well as addiction disorders(Avery et al. 2016).  
Because of the high comorbidity of alcohol use disorders and anxiety disorders—
75% of people that have an AUD reported having a current or prior anxiety disorder 
diagnosis (Kushner et al. 2000; Menary et al. 2011; Swendsen et al. 2010)—the BNST 
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has become a brain region of interest as a possible pharmacological target to alleviate 
alcohol dependence as it is a pivotal structure involved in anxiety states. Several studies 
assessing acute ethanol intake have posited ethanol intake derives from its anxiolytic 
effect (Kushner et al. 2000; Wilson et al. 2004). Subjects with elevated anxiety states are 
significantly more like to engage in increased alcohol drinking in two-bottle choice 
paradigms (Primeaux et al. 2006; Spanagel et al. 1995); chronic anxiety may inspire 
alcohol abuse and lead to the transition to alcohol dependence (Koob 2003). Additionally, 
studies have shown that Alcohol-preferring (P) rats and Sardinian alcohol-preferring (sP) 
rats exhibit enhanced anxiety-like behavior on the EPM, as opposed to non-preferring 
(NP and sNP) lines (Colombo et al. 1995; Stewart et al. 1993). Recurring cycles of 
ethanol exposure and withdrawal have been linked to enhanced anxiety states 
(Kliethermes 2005; Valdez et al. 2002). Alcohol use to alleviate anxiety starts a vicious 
feed-forward cycle that leads to an allostatic state that increases both alcohol use and 
anxiety symptoms (Koob 2008). 
The BNST has been associated with the negative reinforcement aspect of alcohol 
withdrawal. CRF in the CeA and BNST increases during ethanol withdrawal in 
dependent rats through hyperactive non-hypothalamic CRF systems (Funk et al. 2006; 
Merlo Pich et al. 1995; Olive et al. 2002; Zorrilla and Koob 2004). One study used 
central injections to administer CRF-receptor antagonists into ethanol dependent animals 
demonstrated a reduction of withdrawal-induced anxiety-like behavior and ethanol self-
administration (Valdez et al. 2002), suggesting a relationship between ethanol withdrawal 
and the body’s stress system. When administered directly into the BNST, CRF receptor 
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antagonists also attenuate anxiety-like behavior (Rassnick et al. 1993), as well as ethanol 
self-administration (Funk et al. 2006). 
The BNST also plays a role in the reinstatement of substance use after periods of 
abstinence (Koob and Le Moal 2005). Elevations of the early gene c-Fos 
immunoreactivity (marker of neuronal activation) were observed in the BNST following 
the presentation of drug-associated cues (Hill et al. 2007; Mahler and Aston-Jones 2012). 
 
Pituitary Adenylate Cyclase-Activating Peptide (PACAP) 
PACAP was discovered in ovine hypothalamus tissues because of its ability to 
increase adenylyl cyclase activity in the anterior pituitary (Hammack and May 2015; 
Miyata et al. 1989). It is a member of the glucagon/vasoactive intestinal peptide 
(VIP)/secretin peptide superfamily. The PACAP gene’s structure is similar to that of the 
VIP gene (68%) (Lamperti et al. 1991; Miyata et al. 1989), suggesting the genes share a 
common ancestry. PACAP has been shown to have 1000 times the adenylyl cyclase 
activating power as VIP (Miyata et al. 1990). PACAP expression can be found in 
primitive chordates, meaning that its structure and function has been evolutionarily 
preserved (Hammack and May 2015; Sherwood et al. 2000; Vaudry et al. 2009).  
There are two variations of the PACAP peptide, PACAP-27 (27 amino acids) and 
PACAP-38 (38 amino acids), but PACAP-38 is more profuse throughout the body, 
including the central nervous system (Arimura et al. 1991; Hammack and May 2015; 
Miyata et al. 1990). Out of the total peptide found in brain tissue, PACAP 27 represents 
only 10% (Arimura et al. 1991; Ghatei et al. 1993; Masuo et al. 1993; Mikkelsen et al. 
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1995; Piggins et al. 1996).There are currently two classifications for PACAP receptors 
identified: Type I binding sites, which were identified using 125I-PACAP27 as a 
radioligand in the anterior pituitary and hypothalamus exhibit and have a high affinity for 
PACAP38 and PACAP27 (Kd ' 0.5 nM), but a low affinity for VIP (Kd .<500 nM) 
(Cauvin et al. 1990; Gottschall et al. 1991; Gottschall et al. 1990; Lam et al. 1990; Suda 
et al. 1992). Type II binding sites, which have a similar affinity for PACAP and VIP (Kd ' 
1 nM) and found in the brain, as well as  peripheral organs, such as the lung, duodenum, 
and thymus (Gottschall et al. 1990; Hammack and May 2015; Lam et al. 1990; Vaudry et 
al. 2000). 
The densest area of PACAP binding sites and PACAP-containing neurons is 
found in the parvo- and magnocellular neurons of paraventricular and supraoptic nuclei 
of the hypothalamus, which reveals PACAP’s role in neuroendocrine function (Ando et 
al. 1994; Hammack et al. 2010; Kimura et al. 1994; Kivipelto et al. 1992; Ko¨ves K 1991; 
Mikkelsen et al. 1995; Piggins et al. 1996; Vaudry et al. 2000). PACAP-immunoreactive 
fibers are densely present in the internal zone of the median eminence and the area of the 
capillaries of the hypothalamohypophysial portal system (Hannibal et al. 1995; Kivipelto 
et al. 1992; Ko¨ves K 1991; Mikkelsen et al. 1995). Radioimmunoassay (RIA) 
quantification has revealed that in the rat portal blood PACAP concentrations are 
significantly higher than in peripheral blood; this shows PACAP is transported to the 
pituitary when excreted by hypothalamic nerve terminals (Dow et al. 1994). PACAP 
containing neurons are not limited to the hypothalamus; they also reside in the substantia 
nigra, nucleus accumbens, septum, globus pallidus, cerebral piriform cortex, pons, 
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hippocampus, olfactory nuclei, and distinct areas of the amygdala and BNST (Ghatei et 
al. 1993; Hammack et al. 2010; Masuo et al. 1993; Vaudry et al. 2000). 
Many studies have concluded that the behavioral response to stress is heavily 
arbitrated by the PACAP system. Areas of the brain that respond to stress and anxiety are 
highly populated with PACAP and its receptor PAC1 (Arimura et al. 1991; Lezak et al. 
2014a; Nomura et al. 1996; Shioda et al. 1997). Intracerebroventricularly 
(i.c.v.)administration of PACAP, in addition to direct administration into the CeA, PVN, 
and BNST, stimulates a stress response and the hypothalamic–pituitary–adrenal (HPA) 
axis, as well as extrahypothalamic corticotropin-releasing factor (CRF) systems (Agarwal 
et al. 2005; Dore et al. 2013; Missig et al. 2014; Norrholm et al. 2005). 
PACAP fibers synapse on hypothalamic PVN CRF neurons (Legradi et al. 1998) 
and stimulate CRF production and excretion (Agarwal et al. 2005). One study showed 
that after restraint, PACAP null mice exhibited no upregulation of PVN CRF mRNA, as 
opposed to their control counterparts (Stroth and Eiden 2010). This means CRF 
production and release is stimulated by upstream signals from PACAP (Hammack and 
May 2015). PACAP uses the CRF system to exert its effects (Dore et al. 2013). This was 
demonstrated in mice lacking the PACAP and PAC1 receptor gene exhibited weakened 
HPA activation after chronic stress exposure (Hashimoto et al. 2009; Hattori et al. 2012; 
Stroth and Eiden 2010), decreased anxiety behavior (Girard et al. 2006; Hashimoto et al. 
2001; Otto et al. 2001) and a decline in contextual fear conditioning (Lezak et al. 2014a; 
Otto et al. 2001). In addition, infusions of PACAP in the Intra-BNST caused anorexic 
behavior in rats (Kocho-Schellenberg et al. 2014) and anxiety-like behavior (Hammack et 
  13 
al. 2009; Lezak et al. 2014a). In addition, research that observed the effects of repeated 
stress concluded that expression of PACAP and PAC1 receptors were increased in the 
BNST after undergoing repeated stressors, and these changes may underlie the behavioral 
consequences of stress exposure (Hammack et al. 2009; Hammack et al. 2010; Lezak et 
al. 2014b).  
 
The goal of this study was to investigate the effects of intermittent, chronic 
alcohol on PACAP expression in the BNST in both males and female mice. Future 
experiments will elucidate the functional role of these neurochemical alterations in both 
excessive drinking as well as anxiety-like behavior in this animal model. 
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METHODS 
Subjects 
Subjects of this study were male and female C57BL/6J mice, 7 weeks upon 
arrival (Jackson Laboratory Bar Harbor, Maine). Subjects were housed in an AAALAC-
approved vivarium on a 12-h light-dark cycle (lights off at 10:00 a.m.) with water and 
regular rodent chow available ad libitum. Experiments were conducted during the mice’ 
dark cycle. Procedures adhered to the National Institutes of Health Guide for the Care of 
Use of Laboratory Animals and the Principles of Laboratory Animal Care and were 
approved by Boston University Medical Campus Institutional Animal Care and Use 
Committee. 
 
Intermittent Access 20% Ethanol Two Bottle Choice (MWF) 
Ethanol solutions (20% v/v) were prepared using 200 proof ethyl alcohol 
(Pharmco-Aaper) and tap water. Mice were individually housed, and then presented with 
two 50-ml Falcon tubes with rubber stoppers containing stainless steel 5 cm ball-bearing 
sipper tubes (“bottles”), both containing water. 3-5 days later, mice were given 
intermittent access to 20% (v/v) ethanol and water every Monday, Wednesday, and 
Friday, for 24 hours at the beginning of the dark cycle, for 10 consecutive weeks (Fig. 1).  
Bottles were presented to mice at the beginning of the dark cycle (10:00 am), and were 
weighed to the nearest hundredth of a gram both before presentation and 24 hours later, 
shortly before the lights go off. To control for spillage due to experimenter handling or 
evaporation, loss of fluid was assessed in empty cages. During the “off” days, bottles 
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were replaced by two water bottles. Mice were weighed to the nearest hundredth of a 
gram before every ethanol drinking session to calculate the grams of ethanol intake per 
kilogram of body weight.   
  
  16 
Fig. 1 
 
 
Fig. 1: Chronic, intermittent alcohol, two-bottle choice paradigm in the mouse 
home cage.  
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Defensive Withdrawal 
To determine whether anxiogenic-like behavior could be observed during 
withdrawal from ethanol, mice underwent a defensive withdrawal task, 24-30 hours after 
the end of the previous ethanol access. The testing arena was a clear polyvinylchloride 
open field (106 cm × 92 cm × 77 cm) containing a cylindrical darkened “withdrawal” 
chamber (a 250-mL Pyrex beaker shielded from the outside light by wrapping in black 
tape). The “withdrawal” chamber was placed 15 cm from a corner facing the open arena, 
and testing occurred under room light (∼200 lx). Mice were habituated to an anteroom 
adjacent to the testing room for at least 60 min. After habituation, mice were placed 
individually into the withdrawal chamber, facing the back, and then allowed to freely 
explore the arena for 10 min. After every trial, the maze was thoroughly cleaned with 
70% ethanol solution and dried by paper towels. Sessions were video recorded for 
subsequent scoring of latency to emerge from the withdrawal chamber, number of 
withdrawals into the chamber, and total time spent in the chamber by treatment-blind 
raters. 
 
Elevated Plus Maze 
As a second test to assess anxiety-like behavior, the elevated-plus maze (EPM) 
test was used. The apparatus consisted of two open and two enclosed horizontal 
perpendicular arms (30 × 5 cm), positioned 40 cm above the floor. Open arms were dimly 
illuminated (1.5-2 lux). Mice were habituated to an anteroom adjacent to the testing room 
for at least 60 min. After habituation, mice were individually placed in the center of the 
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maze, facing one of the open arms, and allowed to explore for 5 min. After every trial, 
the maze was thoroughly cleaned with 70% ethanol solution and dried by paper towels. 
Sessions were video recorded for subsequent scoring of the number of entries into open 
arms, the time spent in open arms, the number of entries into closed arm, and the time 
spent in closed arms, by treatment-blind raters.  
 
Perfusions  
The mice were anesthetized with isoflurane and transcardially perfused with phosphate 
buffered saline first, followed by 4% paraformaldehyde (PFA). Brains were then 
collected, placed in PFA overnight, and then stored in a 30% sucrose solution in PBS at 4 
°C until saturation.  
 
Immunohistochemistry 
Brains were cut into 30 μm coronal sections using a cryostat, and stored in a 
cryoprotectant solution at −20 °C until processed for immunohistochemistry. Every 4th 
section (120 μm apart; bregma +0.38 to +0.08 mm) of the BNST was collected in a 
systematic manner and processed for immunohistochemistry. After rinsing, incubation in 
0.3% hydrogen peroxide TBS solution to quench endogenous peroxidases, additional 
rinsing, and a blocking step (3% normal goat serum, 0.4% Triton X-100), sections were 
incubated in an anti-PACAP primary antibody in blocking solution for 24 hr at 4  °C 
(1:1,000, Bachem, CA). Sections were then rinsed and incubated in a biotinylated anti-
rabbit secondary antibody (1:500, Vector Labs, Burlingame, CA) in blocking solution, 
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for 2 hr at room temperature. Sections were washed and then incubated in an avidin–
biotin horseradish peroxidase solution (Vector Labs, Burlingame, CA) and 
immunoreactivity was visualized using a diaminobenzidine (DAB) substrate kit (Vector 
Labs, Burlingame, CA) according to the manufacturer’s instructions. Slides were 
dehydrated using graded alcohol concentrations and then cover-slipped.  
 
PACAP Quantification  
The relative density of PACAP-immunoreactivity quantification was performed 
using an Olympus (Center Valley, PA, USA) BX-51 microscope equipped with a Rotiga 
2000R live video camera (QImaging, Surrey, BC, Canada), a three-axis MAC6000 XYZ 
motorized stage (Ludl Electronics, Hawthorne, NY, USA), and a personal computer 
workstation. Bright-field digital images of the anterior BNST were taken at 10× 
magnification using identical light intensity and exposure times. All images were 
imported into ImageJ software and two different area contours were drawn for each 
digital image. One tracing included the BNST positive PACAP immunoreactivity area 
and the other was taken for nonspecific DAB background with no specific PACAP 
staining. Mean optical density was obtained by subtracting the nonspecific DAB 
background from the positive PACAP immunoreactivity. 
 
Statistical analyses 
Ethanol drinking was analyzed using a three-way ANOVA (Session as a within-
subject factor, Group and Sex as between-subjects factors). Data from anxiety tests and 
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from PACAP immunoreactivity were analyzed using a two-way ANOVA (Sex and 
Group as between subjects factors). Statistical significance was set at p<0.05. The 
software/graphic packages used were SigmaPlot 11.0 and Statistica 7.0. 
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RESULTS 
Ethanol drinking in the intermittent access paradigm 
Mice subject to chronic, intermittent access to a 20% v/v ethanol solution and 
water escalated their alcohol intake over time during the 4 weeks (12 sessions) under 
observation (Session: F(17,306)= 5.56, p<0.001). Female mice consumed significantly 
more ethanol than male mice and showed steeper escalation (Sex: F(1,18)=  124.40; 
p<0.001; Sex*Session: F(17,306)= 2.58; p<0.001; Fig 3). By the third day of ethanol 
access, females were consuming significantly more ethanol than males. Average ethanol 
intake across the 6 weeks was higher in female mice, compared to their male counterparts 
(21.4 vs. 13.1 g/kg, respectively). Water intake did not significantly differ between sexes 
(Sex: F(1,18)= 0.05; n.s.), and decreased over time (Session: F(17,306)= 4.04; p<0.001), 
although similarly in the two sexes (Sex*Session: F(17,306)= 0.54; n.s.; Fig 3). Average 
water intake across the 6 weeks was 57.9 and 59.2 ml/kg in females and males, 
respectively. Ethanol preference over time differed between sexes (Sex: F(1,18)= 15.95; 
p<0.001; Fig. 2), and increased over time (Session: F(17,306) = 5.07; p<0.001), although 
similarly in the two sexes (Sex*Session: F(17,306)= 1.08; n.s.). Average ethanol 
preference across the 6 weeks was significantly higher in females (70.2% vs. 58.9% in 
females and males, respectively). Finally, total fluid intake (ml/kg) decreased across days 
(Session: F(17,306)= 2.97, p<0.001). Fluid intake was higher in females (Sex: F(1,18)= 
80.09; p<0.001; Sex*Session: F(17,306)= 1.66, p<0.05). Average fluid intake across days 
was 193.5 and 142.3 ml/kg in females and males, respectively.   
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Fig. 2 
 
 
 
Fig. 2: Male and female C57Bl/6 mice were given access to intermittent access to 
ethanol for 18 sessions, i.e. 6 consecutive weeks (Monday, Wednesday, Friday, 24/hr a 
day, 20% v/v alcohol vs. water) (N = 10/group). A) Both female and male mice escalated 
ethanol intake; female showed higher ethanol intake than males. B) Water intake did not 
differ by sex and decreased over time. C) Female mice had a higher preference for 
ethanol than males; preference increased over time. D) Total fluid intake was higher in 
females. Data are Mean +SEM. Symbols a, b, and c denote p <0.05, p <0.01, p <0.001 vs. 
males, respectively.     
  23 
Anxiety-like behavior in ethanol-withdrawn mice: Defensive withdrawal 
As shown in Fig. 3, an effect of sex could be observed in the latency to first exit 
the withdrawal chamber (Sex: F(1,35)= 9.42, p<0.01); indeed, females displayed lower 
latency to exit compared to control males.  However, ethanol had no effect on latency 
(Group: F(1,35)= 0.11, n.s.; Sex*Group: F(1,35)= 0.07, n.s.). There was also an effect of 
sex on the total time spent in the withdrawal chamber (Sex: F(1,35)= 11.37, p=0.002), 
where females spent less time inside the chamber compared to males (Fig. 4). Ethanol 
had no effect on this measure (Group: F(1,35)= 1.06, n.s.; Sex*Group: F(1,35)= 0.39, 
n.s.).  Alcohol had an effect on the average time spent in the open field during each visit 
(Group: F(1,35) = 8.78, p=0.005; Sex*Group: F(1,35)= 1.92, n.s.), in that ethanol-
drinking males spent longer time outside in each visit compared to controls (Fig. 5). Sex, 
however, had no effect on this measure (Sex: F(1,35)= 0.98, n.s.; Sex*Group: F(1,35)= 
1.92, n.s.). Ethanol had an effect also on the number of transitions from chamber to open 
arena (Group: F(1,35) = 12.21, p=0.001), in that alcohol drinking males showed a 
reduction in number of transitions compared to controls (Fig. 6). Sex had no effect on this 
measure (Sex: F(1,35)= 0.02, n.s.; Sex*Group: F(1,35)= 1.71, n.s.).  
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Fig. 3 
 
 
Fig. 3.  Latency to first exit the chamber in the defensive withdrawal test A) 
Female control mice vs. alcohol-drinking mice showed no differences in latency B) Male 
control mice vs. alcohol-drinking mice had equivalent latencies; male controls had a 
higher latency than female control mice. Data are Mean +SEM. # p <0.05 vs. females of 
same treatment group. 
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Fig. 4 
 
 
Fig. 4: Total time spent in chamber A) Female control mice vs. ethanol drinking 
females were not different in the total time spent in the chamber. B) Male control mice 
vs. ethanol drinking males were not different in the total time spent in the chamber. Data 
are Mean +SEM. ## p <0.01 vs. females of same treatment group. 
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Fig. 5 
 
 
Fig. 5 Average open arena visit length A) Female control mice vs. ethanol 
drinking group had no difference in average arena visit length. B) Male ethanol drinking 
mice had significantly longer arena visits than the male controls. Data are Mean +SEM. 
** p <0.01 vs. Control. 
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Fig. 6 
 
 
Fig. 6. Total transitions in and out of the withdrawal chamber A) Female control 
mice vs ethanol drinking group had similar number of transitions. B) Male control mice 
showed less transitions than the male ethanol drinking group. Data are Mean +SEM.  ** 
p <0.01 vs. Control. 
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Anxiety-like behavior in ethanol-withdrawn mice: Elevated Plus Maze 
An effect of sex*Group in percentage of the total arm time spent on the open arms 
(Sex*Group: F(1,36)= 6.31, p<0.017; Sex: F(1,36)= 1.66, n.s.; Group: F(1,36)= 0.82, 
n.s.) (Fig. 7). Post-hoc analysis showed that ethanol-drinking male mice spent more time 
in the open arms compared to controls. No effects were observed on closed arm entries 
(Sex: F(1,36)= 0.00, n.s.; Group: F(1,36)= 2.30, n.s.; Sex*Group: F(1,36)= 0.02, n.s.) 
(Fig. 8), indicating no differences in locomotor activity among groups.  
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Fig. 7 
 
 
Fig. 7. Percent time in open arms. A) Female control mice vs. ethanol drinking 
group had similar open arm time. B) Control male mice spent less time on the open arms 
than female control mice, and ethanol-drinking male mice spent a higher percentage of 
time in the open arms compared to male control mice. Data are Mean +SEM. #p<0.05, 
vs. females of same treatment group, *p <0.05 vs. controls of same sex.  
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Fig. 8 
 
 
Fig. 8. Number of entries into closed arms of the EPM. A) Female mice control 
vs. ethanol drinking females had a similar number of closed arm entries. B) Male control 
mice vs. ethanol drinking males had a similar number of closed arm entries. Data are 
Mean+SEM. 
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Immunohistochemistry 
As shown in Fig. 9, animals exposed to chronic, intermittent ethanol showed a 
significant increase in their PACAP expression in the BNST area, compared with their 
control counterpart (Group: F(1,19)= 34.39; p< 0.001; Sex*Group: F(1,19)= 0.06, n.s.). 
Female mice exhibited a markedly higher BNST PACAP expression compared to males 
(Sex: F(1,19)= 40.14; p< 0.001). 
 
  
  32 
Fig. 9 
 
 
Fig. 9 PACAP levels in the BNST of control and ethanol drinking C57Bl/6 male 
and female mice. A) PACAP levels were elevated in the BNST of mice exposed to 
chronic, intermittent access to alcohol, compared to Controls (N = 5-8/group). B) 
Representative PACAP staining in BNST of mice (10x). Data are Mean +SEM. *** p 
<0.001 vs. Control; ### p < 0.001 vs. male Control.    
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DISCUSSION 
 
These experiments support the notion that chronic, intermittent alcohol drinking 
recruits the BNST PACAP system in mice. Female mice showed higher intake and 
preference for alcohol compared to male mice in this chronic, intermittent ethanol, two-
bottle choice paradigm. We chose the intermittent ethanol access two bottle choice 
paradigm, because it has been shown to produce escalation of intake, high levels of 
ethanol consumption and preference over a long period of time (Crabbe et al. 2012; 
Simms et al. 2008). This paradigm also consists of repeated binge/intoxication and 
withdrawal cycles through voluntary ethanol intake, as opposed to ethanol vapor 
exposure, which elicits dependence but being experiment-administered does not follow 
the human patterns of alcohol intake. This experiment demonstrated that female mice 
show a higher preference for and intake of alcohol than their male counterparts in the 
two-bottle choice paradigm. Female mice reached average alcohol intake levels of 23-24 
g/kg compared to 12-14 g/kg in male mice.  
Other studies have similarly demonstrated the sexual dimorphisms in alcohol 
consumption; one such study found that female rats of many different breeds maintained 
greater alcohol intake than their male counterparts (Li and Lumeng 1984; Piza-Palma et 
al. 2014). Studies have investigated the role of gender in alcohol consumption through 
ovariectomization and supplementation with estradiol and progesterone (Almeida et al. 
1998). Ovariectomized females display reduced ethanol intake compared to intact 
females, though still higher than males (Almeida et al. 1998).  
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It should be noted that while female animals show a higher prevalence of alcohol 
intake than their male counterparts in a variety of models, humans seem to show the 
opposite trend. Men are more likely to drink alcohol and more likely to binge drink, 
though that gap is quickly closing (Keyes et al. 2010). On the other hand, women 
progress from alcohol use to addiction more quickly, which is termed “telescoping” 
(Brady and Randall 1999). This suggests that women could be more vulnerable to chronic 
alcohol consumption than men.  
Several studies recently focused on the gender-related impairment of the central 
nervous system (Hommer et al. 2001; Pfefferbaum et al. 2001). Despite fewer years of 
heavy drinking than men, the degree of cognitive dysfunction in alcoholic women is 
similar to that in alcoholic men (Nixon and Glenn 1995). In addition, there are studies 
that report similar expansion of intracranial cerebrospinal fluid (CSF) volume among 
male and female alcoholics as opposed to control subjects, though female subjects had 
shorter exposure time to excessive drinking (Hommer et al. 2001; Jacobson 1986; Mann 
et al. 1992) with the use of magnetic resonance imaging showed that the brain volume 
differences between alcoholic and nonalcoholic women were significantly higher than 
those between alcoholic and nonalcoholic men, regardless of female alcoholics reporting 
less years of heavy drinking (Hommer et al. 2001). This suggests that woman may be 
more vulnerable to the aversive effects of alcohol. 
 
Anxiety-like behavioral tests showed unpredicted results. Analyzing with a two-
way ANOVA saw an effect of sex in both latency and time spent in the withdrawal 
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chamber. We hypothesized that we would an effect of group on the latency and time 
spent in the chamber because the mice were tested during a withdrawal period. Female 
mice had a shorter duration of time in the withdrawal chamber and a shorter latency to 
enter open arena. We did, however, observe an effect of group in transitions and average 
time spent in the open field each visit. The effect of group was seen in male mice for 
transitions; female mice showed no significant differences in transitions. Ethanol 
drinking male mice had significantly less transitions than control mice, which could 
reflect either an effect on anxiety-like behavior or on general motor activity. Regarding 
average time spent in the open arena, the effect of ethanol was observed in the male mice. 
In regard to our EPM, there was an effect of sex*group in percentage of total time on 
open arms. Male controls spent significantly less percent of time on the open arms than 
ethanol drinking. We would expect to see the opposite as less time in the open arms is 
usually a sign of anxiety-like behavior. Male control mice also spent significantly less 
percent of time in the open arms compared to females.  
Latency and time in the withdrawal chamber in defensive withdrawal, as well as 
time spent on the open arms on the EPM are normal indicators anxiety-like behavior in a 
subject. Many studies on the sex differences in ethanol use have shown that male subjects 
generally show more anxiety-like behaviors in the EPM (Overstreet et al. 2004) as well 
as social interaction test (Varlinskaya and Spear 2004). In addition, female subjects show 
a lower proclivity to withdrawal, which may be due to the elevated activity of 
progesterone and endogenous steroids (Tanchuck-Nipper et al. 2015). Less intense 
withdrawal symptoms have also been associated with enhanced progesterone and 
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allopregnanolone levels (Martin-Garcia and Pallares 2005). There are also neurochemical 
differences in male and female animal subjects that could account for the discrepancy in 
withdrawal symptoms, such as the increase of GABA alpha-1 receptor in the male rat 
cerebral cortex (Devaud et al. 1997) or the variations of the GluN2B subunit of the 
NMDA receptor in the cortex (Devaud and Morrow 1999). 
We hypothesize that the expected lack of anxiety-like behavior observed in 
ethanol-drinking mice may be a consequence of the time point chosen for the 
observation. Indeed, these tests were performed 24 hr after the end of the previous 
ethanol access, while it is conceivable that anxiety-like behavior may be present at a 
shorter, more acute withdrawal time point in this model. Future experiments will test this 
hypothesis.  
 
These experiments also demonstrate that excessive intermittent alcohol 
consumption causes a marked increase in PACAP immunoreactivity in the oval nucleus 
of the BNST of mice. Indeed, both male and female mice exposed to intermittent ethanol 
access displayed significantly higher levels of PACAP compared to their relative control. 
In addition, PACAP immunoreactivity in control female mice was significantly higher 
compared to male control mice.  
The BNST is an important structure in the stress response and is hypothesized to 
have an important role in AUDs. It is responsible for the synthesizing of mood and 
negative valence information and additionally sustaining anxiety-like behavior; the oval 
nucleus of the BNST receives CRF, GABA, PACAP, dopamine, and encephalin signals 
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(Kim et al. 2013). The oval nucleus sends GABAergic projections to the CeA, VTA, and 
lateral hypothalamus (Dong et al. 2001b). CeA GABAergic neurons, some co-expressing 
CRF (Forray and Gysling 2004), reciprocally project to the oval nucleus of the BNST 
(Daniel and Rainnie 2016). Chronic stress paradigms and foot shock enhance CRF 
mRNA levels in the oval nucleus (Daniel and Rainnie 2016), as well as an upregulation 
of PACAP by more than 10 fold and its receptor PAC1 by 2 fold, in the oval nucleus of 
the BNST, which have been found to engage with CRF-positive neurons (Hammack et al. 
2009; Hammack et al. 2010; Kozicz et al. 1997).  
The next steps of research would be to test the functional role of the PACAP 
increase by administering either PACAP receptor antagonists or an shRNA to knock the 
receptor down directly into the oval nucleus of the BNST, and test their effects on 
excessive alcohol consumption and anxiety-like behavior in mice subject to this drinking 
paradigm. This research, therefore, lays the ground to more extensive work to unravel the 
neurobiology of excessive drinking.    
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